https://www.selleckchem.com/pr....oducts/fluzoparib.ht
001). The incidence of ALK-positive status was 15%, and patients with IPM were more likely to be ALK-positive than patients with SDPLA (35% 5%, P0.001). Compared to IPM, SDPLA more frequently occurred in different lobes (P=0.024), presented with less lymphadenopathy (P=0.014), showed a smaller difference in diameter (Äd) between tumors (P=0.001) and more commonly presented as lobulated tumors (P0.001), spiculated masses (P0.001), ground-glass opacities (GGOs) (P=0.001) and air bronchograms (P=0.02. Patients with SDPLA s
Like
Comment
Share
